Answers are grounded in this paper and cite their sources.
On Dec 23, 2015, WHO prequalified a second affordable oral cholera vaccine (OCV), Euvichol (Eubiologics, South Korea), which is expected to double current global OCV production and has the potential to further increase production capacity.1 The increased production will have implications for vaccine availability and reduced costs per dose, and will ultimately represent an added value for global cholera prevention and control.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: